Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial HypercholesterolemiaBusiness Wire • 04/26/22
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China MarketBusiness Wire • 04/25/22
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung DiseasesBusiness Wire • 03/24/22
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of AsthmaBusiness Wire • 03/15/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWRNewsfile Corp • 03/03/22
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed DyslipidemiaBusiness Wire • 02/24/22
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) InvestigationBusiness Wire • 02/21/22
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated DiseasesBusiness Wire • 02/18/22
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Dr. Christopher Anzalone on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/03/22
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKlineBusiness Wire • 01/24/22
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia SyndromeBusiness Wire • 01/12/22